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Introduction {#Sec2}
------------

About 10% of cancer patients develop metastases in the spine \[[@CR1]\]. The most common site of metastasis in the spine is the thoracic spine (50% to 60% of all metastases), followed by the lumbar (30% to 35%) and cervical spines (10% to 15%) \[[@CR2]-[@CR4]\]. Vertebral metastasis is one of the most serious life-threatening diseases \[[@CR5]\]. About one third of patients with spinal metastases become symptomatic, which means intractable pain, neurological deficits, and/or biomechanical instability requiring surgical treatment \[[@CR3],[@CR6]\].

These nonsurgical methods, such as chemotherapy, radiotherapy, and hormonal therapy, were commonly used for the management of vertebral metastatic disease, which have been proven to be effective in halting the osteolytic process and reversing the neurological compromise \[[@CR7]\]. However, these modalities are unable to provide stability to an instable spinal column and also unable to be expected to relieve pain and spinal cord compression. In these cases, surgery is the best method for the resolution of intractable pain, neurological compromise, and overt or impending spinal instability in patients with spinal metastases. The primary goal of the surgery is to improve patients' quality of life by providing pain relief, maintaining or improving neurological function, and restoring the structural integrity of the spinal column \[[@CR8]\].

Stabilization of the spine is often necessary as extensive lesions may cause spinal instability by erosion of the normal bony structures. The most efficacious therapy for restoring spinal instability is reconstructive surgical intervention. Unfortunately, lots of patients are not considered as candidates for conventional surgery intervention due to neoplasm-associated comorbidities such as malnourishment and a weak immune system that make amounts of surgical procedures unfeasible \[[@CR9]\]. However, these patients can be managed with vertebral augmentation, since it can provide some degree of restabilization \[[@CR10]\].

Vertebroplasty or kyphoplasty, which involves the percutaneous injection of polymethyl methacrylate (PMMA) bone cement into a collapsed vertebral body, is a currently available minimally invasive spine surgery for palliative treatment. Poor surgical candidates with disabling pain secondary to a pathologic thoracic or lumbar vertebral body fracture without epidural compression are ideal candidates for these procedures \[[@CR11]\]. The two procedures have been shown to relieve pain effectively to improve the quality of life, and they can be used as effective palliative treatment even for patients whose general condition is quite poor, with decreased pain, less blood loss, and shorter hospital stays \[[@CR12]\]. On the other hand, their putative benefits with regard to spinal stability and neurological function, as well as their risks affecting their overall survival, have not yet been adequately documented by clinical studies because of limitations such as insufficient spinal cord decompression and stabilizing the vertebral column.

Despite numerous reports on open spinal surgery in treating painful spine metastasis, there exist no randomized controlled comparisons of clinical efficacy and safety between open and minimal access (MIS) procedures. In addition, due to the heterogeneity of study designs, inconsistent reporting of complications, and the use of different grading scales for pain and functional outcomes, it was not possible to perform a meta-analysis using the prospective and retrospective studies. Therefore, we endeavored to perform a quantitative systematic review of the current literature published in the recent 10 years to evaluate the clinical efficacy between MIS and open spinal surgery in patients with spinal metastases. A secondary aim was to compare complication rates between MIS and open spinal surgery.

Materials and methods {#Sec3}
---------------------

Two clinically relevant questions below were determined through a consensus among a panel of spine oncology experts (the Spine Oncology Study Group), and a systematic review of related literature published in the recent 10 years was conducted using PubMed. Specific clinical questions were as follows:In patients with metastatic disease, what is the impact of different surgical approaches (MIS versus open) on alterations of pain and neurologic function?In patients with metastatic disease, what is the impact of different surgical approaches (MIS versus open) on local recurrence, survive rate, and complication?

### Search criteria {#Sec4}

We used the search terms that included "spin\*", "metasta\*", and "surg\*" to searched literature from PubMed. The following terms would be contained: "metastatic", "metastasis", "metastases", "spinal", "spine", "surgery", and "surgical".

Criteria for possible inclusion are as follows: 1) articles published in the recent 10 years, 2) all articles in English or with an English translation, 3) articles with 20 or more subjects, 4) adult age group (18 years and older), 5) articles describing surgical treatment of spinal metastatic cancer, and 6) articles evaluating the alterations of pain and neurologic function postoperatively. Exclusion criteria include the following: 1) primary tumors, 2) intradural tumors, 3) pediatric age group, 4) articles with fewer than 20 subjects, and 5) articles with nonhomogeneous pathology (e.g., trauma and primary tumors in the same series).

Studies were reviewed using a standardized data collection form. The type of study (prospective or retrospective) was noted. Data including surgery technique, the total number of patients, and the type of tumors were totally collected. The methods of pre- and postoperative clinical evaluations with respect to pain and functional outcome were also recorded. All temporary and permanent complications were collected, including major and minor complications. To avoid duplicate records of patients' data, each group or institution was limited to one study in the systematic review. Some authors were contacted directly to clarify certain aspects of their studies.

The quality of evidence for each article was evaluated as high, moderate, low, or very low. The results of the systematic review and ratings of the evidence for each article were determined by a multidisciplinary, international group of spine oncology surgeons, oncologists, and methodologists (Spine Oncology Study Group). The group then went through a consensus-based decision-making process using a modified Delphi technique to arrive at treatment recommendations related to the key clinical questions. This process and the strength of the recommendation were based on the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) method \[[@CR13],[@CR14]\]. These articles were evaluated independently by the authors according to the GRADE criteria.

Result {#Sec5}
------

A total of 1,076 abstracts were identified using various keywords. All abstracts were screened, and 1,013 articles were excluded as obviously unrelated. The full texts of 63 papers were screened and 17 papers were identified to meet the inclusion criteria, including 5 prospective (level II) \[[@CR15]-[@CR19]\] and 12 retrospective articles (level III) \[[@CR20]-[@CR31]\] involving 979 cases of spine metastasis. The details of article selection were presented in Figure [1](#Fig1){ref-type="fig"}. There were 345 cases in 8 studies regarding the clinical evaluation of MIS spinal surgery and 634 cases in 9 studies regarding the clinical evaluation of open spinal surgery for spine metastasis (Table [1](#Tab1){ref-type="table"}). In one study, the primary cancer was breast cancer, whereas in other studies were a mixed group such as lung cancer, prostate cancer, and colon cancer.Figure 1**Flow diagram showing identification of studies included in the review.**Table 1**Characteristics of included studiesStudyYearType of studyQualityNumber of PatientsMean ageProcedurePrimaryOutcomeFollow-up**MinimalPizzoli *et al.* \[[@CR20]\]2009RetrospectiveVery low39NAPVP with PMMAMixedVAS, mobility, analgesic useNAChen *et al.* \[[@CR21]\]2009RetrospectiveVery low3167PVP with PMMAMixedVAS, Karnofsky scale12 monthsQian *et a*l. \[[@CR22]\]2011RetrospectiveVery low4868.5KyphoplastyMixedVAS, ODI, SF-36, vertebral body height variation24 monthsFarrokhi *et al.* \[[@CR15]\]2012ProspectiveVery low2553.5PVP with PMMAMixedVASNATseng *et al.* \[[@CR23]\]2008RetrospectiveVery low5765.18PVP with PMMAMixedVAS, amounts of nonnarcotic and narcotic analgesic6 monthsYang *et al.* \[[@CR16]\]2009ProspectiveVery low4057.63PVP with PMMAMixedVAS, KPS1 yearPflugmacher *et al.* \[[@CR17]\]2008ProspectiveVery low6566Balloon kyphoplastyMixedVAS, ODI24 monthsAnselmetti *et al.* \[[@CR18]\]2013ProspectiveVery low4066.8PVP with PEEKMixedVAS, ODI10 monthsOpenHolman *et al.* \[[@CR24]\]2005RetrospectiveVery low13955Posterior/anterior/combined tumor resection, decompression, instrumentation, fusionMixedVAS, Frankel grades12 monthsChong *et al.* \[[@CR25]\]2012RetrospectiveVery low10558.3Single-stage posterior decompression and stabilizationMixedVAS, Frankel grade, KPS48 monthsEid *et al.* \[[@CR26]\]2011RetrospectiveVery low4553Circumferential decompression and fusion by means of PTAMixedVAS, ASIA grades13 monthsLiang *et al.* \[[@CR27]\]2013RetrospectiveVery low92NAPosterior/anterior/combined tumor resection, decompression, instrumentation, fusionMixedVAS, Frankel grades, Karnofsky score, Tokuhashi scores22 monthsWonik Cho *et al.* \[[@CR28]\]2012RetrospectiveVery low4656.4ACF, ACF and PF, DLF, DLMixedVAS, JOAS, Tomita score39 monthsWalter *et al.* \[[@CR29]\]2012RetrospectiveVery low5758.6Posterolateral approach for decompression combined with posterior instrumentationMixedVAS, Frankel grades, ECOG grades, TPS46 monthsDae-Chul Cho *et al.* \[[@CR30]\]2009RetrospectiveVery low2156.6Posterolateral transpedicular approach with posterior instrumentationMixedVAS, Frankel grades, and ECOG grades13 monthsShehadi *et al.* \[[@CR31]\]2007RetrospectiveVery low8753Posterior/anterior/combined tumor resection, decompression, instrumentation, fusionBreast cancerVAS, Frankel grades13 monthsStreet *et al.* \[[@CR19]\]2007ProspectiveVery low4256.04Single-stage posterolateral vertebrectomyMixedVAS, ECOG gradingNA*PVP* percutaneous vertebroplasty, *PMMA* polymethyl methacrylate, *PEEK* polyetheretherketone, *VAS* visual analog scale, *ODI* Oswestry Disability Index, *JOAS* Japanese Orthopaedic Association Score, *KPS* Karnofsky performance scores, *ASIA* American Spinal Injury Association, *ECOG* Eastern Cooperative Oncology Group, *PTA* posterolateral transpedicular approach, *TPS* Tomita's prognostic score, *ACF* anterior corpectomy and fusion, *ACF and PF* ACF and posterior fixation, *DLF* decompressive laminectomy posterior fixation, *DL* decompressive laminectomy, *NA* not available, *SF-36* Short Form 36 Physical Function.

Among these articles regarding open spinal surgery, three studies were performed with several kinds of approaches such as posterior, anterior, and combined approach to remove tumors in spines. Studies regarding MIS spinal surgery were performed primarily with vertebroplasty whereas two studies \[[@CR22],[@CR17]\] were performed with kyphoplasty.

Pain alleviation was crucially important for the therapy of spine metastases to improve quality of life in patients. A visual analog scale was available for each study to evaluate the effect of pain relief in patients with spine metastases. In all, one study did not display the visual analog scale (VAS) score in detail \[[@CR26]\], and prospective studies had especially detailed pre- and postoperative VAS score. It was found that both MIS and open spinal surgery were efficient in pain alleviation, and most of the studies reported statistically significant improvement (Table [2](#Tab2){ref-type="table"}).Given the high rates of pain alleviation, the results suggest that both MIS and open spinal surgery are efficacious in respect to pain alleviation through decompression and stabilization.Table 2**VAS scores in included studiesStudyPrePostP valueFollow-upPain relief rate**MinimalPizzoli *et al.* \[[@CR20]\]8.62 (±0.71)2.84 (±1.36)NA24 h98%Chen *et al.* \[[@CR21]\]8.9 (±0.93)2.6 (±1.71)*P* \< 0.001NA94%Qian *et al*. \[[@CR22]\]7.4 (±2.1)3.8 ( ±1.6)*P* \< 0.00124 hNA3.2 (±1.0)*P* \< 0.0016 monthsNAFarrokhi *et al.* \[[@CR15]\]8.23 (NA)2.12 (NA)*P* ≤ 0.0524 hNA1 (NA)*P* ≤ 0.052 monthsNATseng *et al.* \[[@CR23]\]8.1 (±0.67)3.8 (±1.9)*P* \< 0.01524 hNA2.8 (±2.0)*P* \< 0.0016 monthsNAYang *et al.* \[[@CR16]\]8.78 (±0.54)5.41 (±0.94)*P* = 0.0326 months95.00%Pflugmacher *et al.* \[[@CR17]\]8.3 (±15)3.3 (±9)*P* \< 0.00013 monthsNAAnselmetti *et al.* \[[@CR18]\]10 (±1)1 (±0.75)*P* \< 0.0011 month100.00%OpenHolman *et al.* \[[@CR24]\]7 (NA)2 (NA)*P* \< 0.0011 month94%Chong *et al.* \[[@CR25]\]6.5 (±1.7)3.4 (±1.6)NA2 weeksNAEid *et al.* \[[@CR26]\]NANANA1 month96%Liang *et al.* \[[@CR27]\]6 (NA)2 (NA)*P* \< 0.00112 months90%Wonik Cho *et al.* \[[@CR28]\]7.86 (±1.05)4.48 (±2.09)*P* = 0.001NANAWalter *et al.* \[[@CR29]\]6.9 (±1.6)3.1 (±1.0)*P* \< 0.0011 month87.70%Dae-Chul Cho *et al.* \[[@CR30]\]6.82 (±2.13)3.61 (±1.01)NA1 monthNAShehadi *et al.* \[[@CR31]\]6 (NA)2 (NA)*P* \< 0.0011 monthNAStreet *et al.* \[[@CR19]\]7.94 (NA)4.3 (NA)*P* \< 0.001NANA

Each study assessed postoperative neurologic function, and multiple methods for evaluating neurologic function were included, such as the Eastern Cooperative Oncology Group performance scale, the Oswestry Disability Index, the Frankel scale, the Karnofsky scale and American Spinal Injury Association grades, the Short Form 36 Physical Function, the Japanese Orthopaedic Association Score, and the Karnofsky performance scores. The neurologic function was not assessed in two studies (Farrokhi *et al.* \[[@CR15]\] and Tseng *et al.* \[[@CR23]\]) regarding MIS surgery. Only nine studies provided pre- and postoperative neurologic function score, and neurologic function was statistically significantly improved (Table [3](#Tab3){ref-type="table"}). Other studies without detailed data also showed that MIS and open spinal surgery were successful in improving physical function.Table 3**Neurologic function evaluation in included studiesStudyMethodScale best to worstFunctional outcome*P*** **value**MinimalPizzoli *et al.* \[[@CR20]\]Mobility1 to 4Preoperative: 3.25 ± 0.59, postoperative: 1.24 ± 0.64*P* \< 0.001Chen *et al.* \[[@CR21]\]Karnofsky scale100 to 0Preoperative: 50 ± 10.65, postoperative: 70 ± 3.59NAQian *et al.* \[[@CR22]\]ODI0 to 100Preoperative: 71.5 ± 16.7, postoperative: 29.5 ± 10.2*P* \< 0.001SF-36100 to 0Preoperative: 34.3 ± 10.8, postoperative: 54.5 ± 10.5*P* \< 0.05Yang *et al.* \[[@CR16]\]Karnofsky scale100 to 0Preoperative: 69.4 ± 8.3, postoperative: 80.3 ± 7.2*P* = 0.002Pflugmacher *et al.* \[[@CR17]\]ODI0 to 100Preoperative: 81 ± 8, postoperative: 39 ± 7*P* \< 0.0001Anselmetti *et al.* \[[@CR18]\]ODI0 to 100Preoperative: 82.2, postoperative: 4.1*P* \< 0.001OpenHolman *et al.* \[[@CR24]\]Frankel gradeE to A46/112 (41%) improved at least one Frankel grade, 20/112 (18%) regained ambulation, seven (5%) worsened*P* \< 0.05Chong *et al.* \[[@CR25]\]Frankel gradeE to A21/105 (20%) improved at least one Frankel grade, 21/105 (48%) regained ambulation, 6/105 (5.7%) worsened*P* \< 0.05Eid *et al.* \[[@CR26]\]ASIA gradeE to A23/45 (51%) improved one or more grades, 6/45 (20%) retained their preoperative grade, one (3%) experienced worsening*P* \> 0.05Liang *et al.* \[[@CR27]\]Karnofsky scores100 to 0The median postoperative Karnofsky scores increased from 60 (range, 40 to 80) to 70 (range, 0 to 80)*P* \< 0.001Frankel gradeE to A78% improved 1.2 grades at averageNAWonik Cho *et al.* \[[@CR28]\]JOAS10 to 0Preoperative: 13.11 ± 2.75, postoperative: 15.17 ± 2.09*P* = 0.001Walter *et al.* \[[@CR29]\]Frankel gradeE to A13 (22.8%) patients improved, 43 (75.5%) had a stable neurological status, one single patient (1.8%) experienced worseningNAECOG grade0 to 5Preoperative: 2.0 ± 1.1, postoperative: 1.7 ± 1.3*P* \< 0.05Dae-Chul Cho *et al.* \[[@CR30]\]Frankel gradeE to A7/22 (33.3%) improved, 14/21 (66.7%) had a stable neurological statusNAECOG grade0 to 58 had an improved ECOG grade, and 12 showed no change, 1 experienced worseningNAShehadi *et al.* \[[@CR31]\]Frankel gradeE to A85% maintained or improved their Frankel scoresNAStreet *et al.* \[[@CR19]\]ECOG grade0 to 5Preoperative: 2.5 ± 1.0, postoperative: 1.6 ± 0.75NA*ODI* Oswestry Disability Index, Japanese Orthopaedic Association Score, *ECOG* Eastern Cooperative Oncology Group, *NA* not available, *SF-36* Short Form 36 Physical Function.

It is reported that decreased complication rates are considered to be one of the advantages of MIS spinal surgery. This was confirmed by the evidences we provided in this systematic review. There are no major complications for MIS spinal surgery except in two studies \[[@CR20],[@CR23]\], whereas six studies regarding open spinal surgery reported major complications with a trend of lower survive rates and higher recurrence rates (Table [4](#Tab4){ref-type="table"}).Table 4**Serious complications in included studies (excluding deaths)StudyRecurrenceSurvivalComplications**MinimalPizzoli *et al.* \[[@CR20]\]5.1%NAThree major complications (one pneumothorax and two symptomatic leakages) (2.8%), two minor complications (cement pulmonary embolism) (1.8%)Chen *et al.* \[[@CR21]\]NA74% at 6 months, 39% at 12 monthsNo major complicationQian *et al.* \[[@CR22]\]No81% at 2 yearsNo major complications, cement leakage (18.6%)Farrokhi *et al.* \[[@CR15]\]NANACement leakage (44%)Tseng *et al.* \[[@CR23]\]NATwo patients died during hospitalizationCement extravasation (17.9% minor extravasation, 3.9% major extravasation)(21.8%)Yang *et al.* \[[@CR16]\]No80.0% at 1 yearSeven paravertebral cement leakage (17.5%)Pflugmacher *et al.* \[[@CR17]\]80.0% at 1 year, 66% at 2 yearsCement leakage (12.1%), adjacent incident fracture (8%)Anselmetti *et al.* \[[@CR18]\]20%85% at 3 monthsCement leakage (16.3%)OpenHolman *et al.* \[[@CR24]\]8%Mean survival was 14.8 months, 67% at 0.5 months, 54% at 1 month, 23% at 5 yearsMajor complications (18%) and minor complications (21%)Chong *et al.* \[[@CR25]\]NAMedian survival was 6.0 months, 34% at 1 year, 14% at 2 years survival ratesSurgical complications occurred in patients (10%), no mechanical failureEid *et al.* \[[@CR26]\]NoMean survival was 13 monthsUnstable (15.5%), wound infection (15.5%), hematoma (4%) and deep vein thrombosis (2%)Liang *et al.* \[[@CR27]\]NAThe median survival was 15 months, 61% at 1 year, and 35% at 3 yearsMajor complications (23%)Wonik Cho *et al.* \[[@CR28]\]39.10%Mean survival was 11.82 months, 44.4% at 6 months, 35.6% at 12 months, and 19.0% at 24 monthsTwo operation site infection, two pneumonia, one esophageal fistula after anterior approach (10.9%)Walter *et al.* \[[@CR29]\]1.70%Mean survival was 11.4 months, 42.1% at 1 yearSuperficial wound infections and one seroma (5.3%)Dae-Chul Cho *et al.* \[[@CR30]\]14%Mean survival was 8.9 monthsOne wound infection and one wound dehiscence (9.5% )Shehadi *et al.* \[[@CR31]\]11.50%Median survival was 21 months, 62% at 1 year, 33% at 3 years, and 24% at 5 yearsMajor complications by surgical approach (17%)Street *et al.* \[[@CR19]\]2.30%75% at 6 months and 50% at 12 monthsMajor complications (26%)*NA* not available.

Discussion {#Sec6}
----------

For most of the patients with spinal metastasis, the treatment is largely palliative and aims to achieve relief of pain and regain function, thus improving the quality of the life of the patients. Because of the immunocompromised status, poor nutrition, and comorbid medical conditions, many patients with spinal metastasis cannot tolerate the curative surgical methods. In recent years, more and more minimally invasive spinal interventions are reasonable alternatives to open spinal surgery for treating spinal metastatic tumors. These procedures can contribute to less soft tissue trauma, lower blood loss, and shorter hospitalization time. MIS spinal surgery rarely interferes with the adjuvant treatments. The overall morbidity is considerably lower in comparison to conventional spine surgery.

Despite this evolution, questions surrounding the effectiveness of MIS and its comparability to open spinal surgery in terms of pain and neurologic function remain unanswered. A direct comparison of clinical efficiency and safety between open and MIS spinal surgery for spinal metastasis has never been conducted. Given the lack of comparison studies, we aimed to compare the effect of pain alleviation and functional improvement between open and MIS spinal surgery by reviewing published studies in a quantitative manner. Our results suggest that open or MIS spinal surgery is likely to achieve the improvement in pain and neurological dysfunction for spinal metastasis, but open surgery seems to involve more major complications with a trend of lower survival rates and higher recurrence rates compared to MIS surgery.

There are few comparison studies between MIS and open spinal surgery. Huang *et al.* \[[@CR32]\] performed a direct retrospective comparison of MOT, MBL, LOS, and CR for MIS versus open spinal surgery for thoracic spine metastasis, and no significant difference was found. However, the amount of patients requiring at least a 2-day admission in the open group was significantly larger than that of the MIS group (open: 88% versus MIS: 6.9%). If there is truth that there is no significant difference in the functional outcome between the MIS and open group, the possible reason is that the potential benefit of MIS is counteracted by the more complicated nature of patients with metastatic spine disease during operation \[[@CR33]\]. Payer *et al.* \[[@CR34]\] also demonstrated that mean blood loss, operative time, and complication rates in spinal tumor patients were higher than that of the fracture patients with anterior approach.

Conclusions {#Sec7}
===========

In conclusion, we performed the systematic review based on literature published in the recent 10 years to possibly compare clinical efficiency and complication rate between open and MIS spinal surgery for spine metastasis and found that both open spinal surgery and MIS seem to achieve the improvement of pain and neurological dysfunction through decompression and stabilization, but open surgery may involve more major complications with a trend of lower survival rates and higher recurrence rates compared to MIS. However, it is necessary to perform a controlled study to compare the clinical efficiency between the two procedures for spine metastasis in the future.
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